Recruiting
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
NCT06912087
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +12 more
- Locations
-
- University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States